Viaderma Inc (OTCMKTS:VDRM) is a sub-penny stock that has started to garner attention as shares blast up the chart. The key catalyst in recent days is the company’s announcement that CEO Dr. Christopher Otiko filed a patent application in mid-December with the USPTO for its proprietary innovative transdermal delivery system. Shares seem to have reacted very well to the news, roughly tripling in recent days in response.
According to the company’s release, ViaDerma has also signed licensing and distribution agreements with two Pharmaceuticals companies for its FDA registered drug, Viabecline. The OTC topical antibiotic is capable of significant healing results in just 10 days of treatment by combing a common FDA approved antibiotic, Tetracycline, with ViaDerma’s proprietary transdermal delivery system. ViaDerma is seeing amazing penetration and absorption at the localized wound area. “We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido,” said CEO Dr. Christopher Otiko.
Viaderma Inc (OTCMKTS:VDRM) bills itself as a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.
ViaDerma’s lead product, TetraStem, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets.
The company is moving aggressively into the medicinal marijuana space.
According to company materials, “ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma’s lead product, Viabecline, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. Also, Patent application using the combination of CBD’s and THC with the delivery system was filed in 2014. The use of CBD’s is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.”
Find out when $VDRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
This is an interesting play in the biotech space at present given the potential range of applications for the core tech, and the degree to which we can assume new press releases might come forth in a deluge to the extent the company sees further support for its basic functionality.
“ViaDerma is ready to move forward in 2017. We are taking an aggressive growth path this year with product licensing deals that we expect to increase our revenue growth. We have many opportunities with the use of our proprietary transdermal delivery system for specialized treatments and continuing studies. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community,” said Dr. Christopher Otiko, ViaDerma’s founder and CEO.
Viabecline is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs.
The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as ‘staph infections.’ Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.
Recent action has seen a bit less than 370% added to share values of the name over the past week of action, a rally that has pushed up against longer standing distributive pressure in the stock. This is emblematic of the stock. VDRM has evidenced sudden upward volatility on many prior occasions. Moreover, the listing has registered increased average transaction volume recently, with the past month seeing a bit less than 430% over the long run average.
Earning a current market cap value of $2.1M, VDRM has virtually no cash on the books, which must be weighed relative to about $217K in total current liabilities. VDRM is pulling in trailing 12-month revenues of $306K. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 8.8%. As more color becomes clear on the name, we will review the situation and update our take. For continuing coverage on shares of $VDRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!